Navigating Cannabis Rescheduling: Key Insights for Healthcare

Kathryn J. Russo & Catherine A. Cano Details November 7, 2024 Earlier this year, the DEA responded to President Biden’s directive to reschedule cannabis from Schedule I to Schedule III of the Controlled Substances Act. This pivotal change, if finalized, would reclassify marijuana as a drug with moderate to low potential for dependence, strictly for medical use. […]